Impact of rivaroxaban on stent thrombosis and secondary prevention of cardiovascular events in acute coronary syndrome
Clicks: 333
ID: 6800
2014
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Popular Article
74.7
/100
333 views
266 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Impact of rivaroxaban on stent thrombosis and secondary prevention of cardiovascular events in acute coronary syndrome Marvin Krohn-Grimberghe, Christoph Bode, Constantin von zur MuhlenDepartment of Cardiology and Angiology I, Heart Center, University of Freiburg, GermanyAbstract: Angioplasty and stent implantation have greatly improved the outcome of patients with acute coronary syndrome. However, stents come with the risk of stent thrombosis, which is associated with a high rate of revascularization, myocardial infarction, and death. The inhibition of factor Xa due to rivaroxaban leads to an interruption of the intrinsic as well as the extrinsic coagulation pathway, which reduces thrombus formation as a potential mechanism to diminish the rate of stent thrombosis. In this review, we evaluate the role of rivaroxaban in the prevention of stent thrombosis and its general role in patients with acute coronary syndrome.Keywords: Rivaroxaban, stent thrombosis, acute coronary syndrome, secondary preventionReference Key |
marvin2014impactresearch
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
---|---|
Authors | Marvin Krohn-Grimberghe;Christoph Bode;Constantin von zur Muhlen and |
Journal | research reports in clinical cardiology |
Year | 2014 |
DOI | 10.2147/RRCC.S38727 |
URL | |
Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.